keyword
MENU ▼
Read by QxMD icon Read
search

Ivabradine AND Heart failure

keyword
https://www.readbyqxmd.com/read/28205056/analyzing-health-related-quality-of-life-data-to-estimate-parameters-for-cost-effectiveness-models-an-example-using-longitudinal-eq-5d-data-from-the-shift-randomized-controlled-trial
#1
Alison Griffiths, Noman Paracha, Andrew Davies, Neil Branscombe, Martin R Cowie, Mark Sculpher
INTRODUCTION: The aim of this article is to discuss methods used to analyze health-related quality of life (HRQoL) data from randomized controlled trials (RCTs) for decision analytic models. The analysis presented in this paper was used to provide HRQoL data for the ivabradine health technology assessment (HTA) submission in chronic heart failure. METHODS: We have used a large, longitudinal EuroQol five-dimension questionnaire (EQ-5D) dataset from the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT) (clinicaltrials...
February 15, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28185709/heart-failure-guidelines-what-s-new
#2
REVIEW
Lampros Papadimitriou, Carine E Hamo, Javed Butler
Heart Failure is a global epidemic, affecting approximately 5 million adults in the U.S.A. The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomic systems. The 2016 focused pharmacologic update on the current Heart Failure Guidelines introduces the use of two newly approved regimens valsartan/sacubitril and ivabradine. Over the last two decades, guideline directed medical therapy has accomplished significant improvement in survival rates among heart failure patients; however these novel compounds were reported to exert additional mortality and morbidity benefits, in heart failure subpopulations with reduced ejection fraction...
January 11, 2017: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28115808/the-effects-of-ivabradine-on-left-ventricular-synchronization-and-tei-index-in-patients-with-systolic-heart-failure
#3
Fatma Hizal Erdem, Serkan Ozturk, Selçuk Öztürk, Alim Erdem, Selim Ayhan, Mustafa Öztürk, İbrahim Dönmez, Davut Baltacı, Mehmet Yazıcı
BACKGROUND: The aim of our study was to evaluate in stable outpatients with systolic heart failure (HF) the 3 months effect of ivabradine on LV synchronization and Tei index in stable outpatients with systolic HF. METHODS: We evaluated prospectively 40 (30 males, 10 females) patients with HF. All patients were evaluated before and after treatment by transthoracic M mode, two dimensional (2D), pulsed-wave (PW), continuous wave (CW), color flow and tissue Doppler imaging (TDI) and tissue synchronization imaging (TSI)...
January 2017: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/27984253/does-heart-rate-really-matter-to-patients-with-heart-failure
#4
Robert J H Miller, Jonathan G Howlett
PURPOSE OF REVIEW: Measurement of heart rate (HR) and rhythm is used to identify patients at increased risk of disease progression, guide selection of treatments and gauge response to therapy. RECENT FINDINGS: Lowering HR with a pure HR lowering agent (ivabradine) in heart failure with reduced ejection fraction (HFrEF) and sinus rate more than 70 beats/min despite beta blockade has been shown to improve outcomes. Additionally, coadministration of ivabradine and beta blockade may enhance symptoms and HR control...
March 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/27982270/elevated-heart-rate-is-associated-with-cardiac-denervation-in-patients-with-heart-failure-a-123-iodine-mibg-myocardial-scintigraphy-study
#5
Aline Sterque Villacorta, Humberto Villacorta, Jenne Serrão de Souza, José Antônio Caldas Teixeira, Maria Clara S S S Muradas, Christiane Rodrigues Alves, Bernardo Campanário Precht, Pilar Porto, Letícia Ubaldo, Cláudio Tinoco Mesquita, Antônio Cláudio Lucas da Nóbrega
Background: In the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT), heart rate (HR) reduction with ivabradine was associated with improved survival and reduced hospitalizations in patients with heart failure (HF). The mechanisms by which elevated HR increases mortality are not fully understood. Objective: To assess the relationship of baseline HR with clinical, neurohormonal and cardiac sympathetic activity in patients with chronic HF and elevated HR...
November 2016: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/27972043/systematic-review-of-cost-effectiveness-analysis-of-ivabradine-in-heart-failure
#6
M Dehghani, M Varmaghani, F Sharifi
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27895488/advances-in-the-management-of-heart-failure-the-role-of-ivabradine
#7
REVIEW
Ursula Müller-Werdan, Georg Stöckl, Karl Werdan
A high resting heart rate (≥70-75 b.p.m.) is a risk factor for patients with heart failure (HF) with reduced ejection fraction (EF), probably in the sense of accelerated atherosclerosis, with an increased morbidity and mortality. Beta-blockers not only reduce heart rate but also have negative inotropic and blood pressure-lowering effects, and therefore, in many patients, they cannot be given in the recommended dose. Ivabradine specifically inhibits the pacemaker current (funny current, If) of the sinoatrial node cells, resulting in therapeutic heart rate lowering without any negative inotropic and blood pressure-lowering effect...
2016: Vascular Health and Risk Management
https://www.readbyqxmd.com/read/27867524/varying-effects-of-recommended-treatments-for-heart-failure-with-reduced-ejection-fraction-meta-analysis-of-randomized-controlled-trials-in-the-esc-and-accf-aha-guidelines
#8
REVIEW
Marius Mark Thomsen, Christian Lewinter, Lars Køber
The aim of this paper is to evaluate the treatment effects of recommended drugs and devices on key clinical outcomes for patients with heart failure with reduced ejection fraction (HFREF). Randomized controlled trials (RCTs) listed in the 2012 HF guideline from the European Society of Cardiology as well as the 2013 HF guideline from the American College of Cardiology Foundation and American Heart Association were evaluated for use in the meta-analysis. RCTs written in English evaluating recommended drugs and devices for the treatment of patients with HFREF were included...
December 2016: ESC Heart Failure
https://www.readbyqxmd.com/read/27846461/ivabradine-as-adjuvant-treatment-for-chronic-heart-failure
#9
Carolina C Mizzaci, Gustavo J M Porfírio, André T Vilela, José Cícero S Guillhen, Rachel Riera
BACKGROUND: Heart failure prevalence is rising throughout the world. Despite current multidrug therapy, heart failure is the cause of frequent hospitalizations and high mortality. OBJECTIVES: To assess the effectiveness and safety of ivabradine in chronic heart failure. METHODS: We searched the databases: the Cochrane Central Register of Controlled Trials CENTRAL (The Cochrane Library), MEDLINE, EMBASE, CINAHL, Conference Proceedings Citation Index - Science and Science Citation Index Expanded on Web of Science and LILACS...
January 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/27825166/the-effects-of-ivabradine-on-cardiac-function-after-myocardial-infarction-are-weaker-in-diabetic-rats
#10
Xue Cao, Zhijun Sun, Boya Zhang, Xueqi Li, Hongyuan Xia
BACKGROUND/AIMS: Plasma norepinephrine (NE) and brain natriuretic peptide (BNP, termed BNP-45 in rats) are considered as essential neurohormones indicating heart failure progression. The purposes of this study were to examine the effects of ivabradine (IBD) on cardiac function and plasma NE and BNP-45 after chronic ischemic heart failure (CHF) in non-diabetic rats and diabetic rats. We further determined if sympathetic NE uptake-1 (a major pathway to metabolize NE) mechanism is responsible for the role played by IBD...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27822484/impact-of-ivabradine-on-inflammatory-markers-in-chronic-heart-failure
#11
Ilonka Rohm, Daniel Kretzschmar, Rudin Pistulli, Marcus Franz, P Christian Schulze, Christian Stumpf, Atilla Yilmaz
Background. Inflammation plays a crucial role in the progression of chronic heart failure (CHF). Ivabradine is known to reduce the morbidity and mortality of patients with CHF under certain conditions. Beyond the reduction of heart rate, only limited knowledge exists about potential anti-inflammatory effects of ivabradine that might contribute to its benefit in CHF. Thus, the present study aimed to investigate the effect of ivabradine on systemic inflammation. Methods. In the present study, 33 patients with CHF due to dilated, ischemic, and hypertensive cardiomyopathy were treated with ivabradine according to the guidelines of the European Society of Cardiology (ESC)...
2016: Journal of Immunology Research
https://www.readbyqxmd.com/read/27784216/ivabradine-a-current-overview
#12
Kaushik Guha, Christopher J Allen, Adam Hartley, Rakesh Sharma
Ivabradine, acting on the funny channel in the sino-atrial node, is a promising drug in the treatment of ischaemic heart disease and heart failure. There has been much clinical research conducted exploring its role in these fields. This review discusses the drug development and trial data, and highlights future directions for research.
October 25, 2016: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/27780557/benefits-of-heart-rate-slowing-with-ivabradine-in-patients-with-systolic-heart-failure-and-coronary-artery-disease
#13
REVIEW
Jeffrey S Borer, Prakash C Deedwania, Jae B Kim, Michael Böhm
Heart rate (HR) is a risk factor in patients with chronic systolic heart failure (HF) that, when reduced, provides outcome benefits. It is also a target for angina pectoris prevention and a risk marker in chronic coronary artery disease without HF. HR can be reduced by drugs; however, among those used clinically, only ivabradine reduces HR directly in the sinoatrial nodal cells without other known effects on the cardiovascular system. This review provides current information regarding the safety and efficacy of HR reduction with ivabradine in clinical studies involving >36,000 patients with chronic stable coronary artery disease and >6,500 patients with systolic HF...
December 15, 2016: American Journal of Cardiology
https://www.readbyqxmd.com/read/27769970/evolving-therapies-for-the-management-of-chronic-and-acute-decompensated-heart-failure
#14
Jennifer C Cook, Richard H Tran, J Herbert Patterson, Jo E Rodgers
PURPOSE: The pharmacology, clinical efficacy, and safety profiles of evolving therapies for the management of chronic heart failure (HF) and acute decompensated heart failure (ADHF) are described. SUMMARY: HF confers a significant financial burden despite the widespread use of traditional guideline-directed medical therapies such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, and aldosterone receptor antagonists, and the rates of HF-related mortality and hospitalization have remained unacceptably high...
November 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27766510/ivabradine-in-patients-with-stable-coronary-artery-disease-a-rationale-for-use-in-addition-to-and-beyond-percutaneous-coronary-intervention
#15
REVIEW
Cosmo Godino, Antonio Colombo, Alberto Margonato
Heart rate is an established prognostic marker for longevity and is an important contributor in the pathophysiology of various cardiovascular diseases, including ischemic heart disease and heart failure. Most ischemic episodes are triggered by an increase in heart rate, which causes an imbalance between myocardial oxygen delivery and consumption. In addition, increased heart rate is a modifiable risk factor for chronic heart failure. Ivabradine, an inhibitor of If ion channels, is an approved second-line anti-ischemic drug for the treatment of angina...
February 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27752846/ivabradine
#16
Michel Komajda
Ivabradine is a blocker of the funny current channels in the sinoatrial node cells. This results in pure heart rate reduction when elevated without direct effect on contractility or on the vessels. It was tested in a large outcome clinical trial in stable chronic heart failure (CHF) with low ejection fraction, in sinus rhythm, on a contemporary background therapy including betablockers (SHIFT: Systolic Heart Failure Treatment with the If inhibitor Trial).The primary composite endpoint (cardiovascular mortality or heart failure hospitalization) was reduced by 18% whereas the first occurrence of heart failure hospitalizations was reduced by 26%...
October 18, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27733074/financial-impact-of-ivabradine-on-reducing-heart-failure-penalties-under-the-hospital-readmission-reduction-program
#17
Anuraag R Kansal, Stanimira Krotneva, Ali Tafazzoli, Harshali K Patel, Jeffrey S Borer, Michael Böhm, Michel Komajda, Juan Maya, Luigi Tavazzi, Ian Ford, Adrian Kielhorn
OBJECTIVE: The introduction of the Hospital Readmission Reduction Program (HRRP) has led to renewed interest in developing strategies to reduce 30 day readmissions among patients with heart failure (HF). In this study, a model was developed to investigate whether the addition of ivabradine to a standard-of-care (SoC) treatment regimen for patients with HF would reduce HRRP penalties incurred by a hypothetical hospital with excess 30 day readmissions. RESEARCH DESIGN: A model using a Monte Carlo simulation framework was developed...
February 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27725624/a-treatment-approach-for-patients-with-chronic-systolic-heart-failure
#18
Barry H Greenberg
The treatment of heart failure with reduced ejection (HFrEF) is changing rapidly. Advances over the past several decades have focused on blocking the adverse effects of neurohormonal activation. This approach has resulted in marked improvement in outcomes in the HFrEF population. Despite these advances, however, mortality and morbidity remain high and HFrEF patients have poor quality of life. New approaches to therapy now offer additional benefits. Combined neprilysin inhibition and angiotensin receptor blockade using sacubitril-valsartan (LCZ696) has been shown to be superior to an angiotensin-converting enzyme inhibitor in HFrEF patients...
2016: Reviews in Cardiovascular Medicine
https://www.readbyqxmd.com/read/27719379/a-model-to-assess-the-cost-effectiveness-of-pharmacogenomics-tests-in-chronic-heart-failure-the-case-of-ivabradine
#19
Ange C Iliza, Alexis Matteau, Jason R Guertin, Dominic Mitchell, Fiorella Fanton-Aita, Anick Dubois, Marie-Pierre Dubé, Jean-Claude Tardif, Jacques LeLorier
Pharmacogenomics (PGx) tests have the potential of improving the effectiveness of expensive new drugs by predicting the likelihood, for a particular patient, to respond to a treatment. The objective of this study was to develop a pharmacoeconomic model to determine the characteristics and the cost-effectiveness of a hypothetical PGx test, which would identify patients who are most likely to respond to an expensive treatment for chronic heart failure. For this purpose, we chose the example of ivabradine. Our results suggest that the use of a PGx test that could select a subgroup of patients to be treated with an expensive drug has the potential to provide more efficient drug utilization...
October 10, 2016: Pharmacogenomics
https://www.readbyqxmd.com/read/27701079/heart-failure-therapy-in-2016-shifting-the-paradigm-from-antiquated-therapies-toward-novel-agents
#20
Douglas L Jennings
Heart failure (HF) continues to afflict millions of Americans, resulting in substantial clinical and economic burden to our society. Recent literature has highlighted the role of 2 novel therapies (an angiotensin receptor blocker/neprilysin inhibitor and ivabradine) in further reducing residual disease in HF. Simultaneously, evidence has mounted suggesting that older therapies like digoxin are not effective in contemporary practice and, in fact, may be harmful. This editorial summarizes the most recently published articles pertaining to both new and old HF therapies and provides a call to action to pharmacists on how to shift patients toward effective drug regimens...
October 3, 2016: Annals of Pharmacotherapy
keyword
keyword
76071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"